Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - warfarin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - warfarin sodium -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 40 mg/ml;  ;   - powder for oral suspension - 40 mg/ml - active: voriconazole 40 mg/ml     excipient: citric acid colloidal silicon dioxide orange flavour 57458 ap05514 sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine tartrate -

Malta - English - Medicines Authority

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - warfarin sodium - tablet - warfarin sodium 1 mg - antithrombotic agents

Malta - English - Medicines Authority

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - warfarin sodium - tablet - warfarin sodium 3 mg - antithrombotic agents

Malta - English - Medicines Authority

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - warfarin sodium - tablet - warfarin sodium 5 mg - antithrombotic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - trastuzumab emtansine 100mg (plus 6% vial overfill = trastuzumab emtansine 106mg) - powder for infusion - 100 mg - active: trastuzumab emtansine 100mg (plus 6% vial overfill = trastuzumab emtansine 106mg) excipient: polysorbate 20 sodium hydroxide succinic acid sucrose - kadcyla as a single agent, is indicated for the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included her2-targeted therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - trastuzumab emtansine 160mg (plus 7% vial overfill = trastuzumab emtansine 171mg) - powder for infusion - 160 mg - active: trastuzumab emtansine 160mg (plus 7% vial overfill = trastuzumab emtansine 171mg) excipient: polysorbate 20 sodium hydroxide succinic acid sucrose - kadcyla as a single agent, is indicated for the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included her2-targeted therapy.